Autism Spectrum Disorder Therapeutics Market To Surpass US$ 5,225.5 Million By 2027

SEATTLE - July 1, 2021 - PRLog -- Global Autism Spectrum Disorder Therapeutics Market, by Drug Type (Aripiprazole, Risperidone, Melatonin, CM-AT, Bumetanide, and Balovaptan), by Age Group (Child and Adult), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$  2,285.5 million in 2019 and is projected to exhibit a CAGR of 10.9% over the forecast period (2019 - 2027).

Increasing investigational research and funding support for pharmacogenomics-based drug discovery is a major factor driving growth of the autism spectrum disorder therapeutics market.  Various organizations are focused on receiving approvals to investigate novel drugs for the treatment of ASD. For instance, in January 2018, Roche announced that the U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation for its investigational oral medicine balovaptan, a vasopressin 1a (V1a) receptor antagonist for individuals with ASD. Balovaptan demonstrated potential to improve social interaction and communication in people with ASD.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2643

Increasing funding for the research of ASD drugs is expected to contribute in the ASD therapeutics market size.  Hoffmann-La Roche, Basel. Manufacturers in the autism spectrum disorder therapeutics market are focused on adopting collaboration and partnership strategies to enhance their market share.

Furthermore, government organizations are focused on conducting workshops for parents and caregivers of children with developmental disorders, which is expected to aid in the ASD therapeutic market growth. For instance, a workshop jointly led by Pan American Health Organization, World Health Organization, and Autism Speaks is organized annually in the month of August in Buenos Aires, Argentina, to teach skills and raise awareness about autism and its preventive measures.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/autism-spectrum-disorder-therapeutics-market-2643

Key Takeaways of the Autism Spectrum Disorder Therapeutics Market:

The global autism spectrum disorder therapeutics market is expected to witness a CAGR of 10.9% during the forecast period (2019–2027), owing to increasing drug approvals, investigational studies, and funding

Major players operating in the global autism spectrum disorder therapeutics market include, F. Hoffmann-La Roche AG, Neurim Pharmaceuticals, Inc., Yamo Pharmaceuticals LLC, Servier Laboratories Ltd., Otsuka Holdings Co. Ltd., Curemark LLC, Oryzon Genomics S.A., GW Pharmaceuticals Plc., Teva Pharmaceutical Industries Ltd., Zynerba Pharmaceuticals Inc., Stalicla SA., Novartis AG, Pfizer, Inc., and Bristol Myers Squibb.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2643